109 related articles for article (PubMed ID: 38820707)
1. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.
Musallam KM; Barella S; Origa R; Ferrero GB; Lisi R; Pasanisi A; Longo F; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2024 Jul; 107():102859. PubMed ID: 38820707
[TBL] [Abstract][Full Text] [Related]
2. Deferasirox for managing iron overload in people with thalassaemia.
Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
[TBL] [Abstract][Full Text] [Related]
3. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Neufeld EJ
Blood; 2006 May; 107(9):3436-41. PubMed ID: 16627763
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
Premawardhena A; Perera C; Wijethilaka MN; Wanasinghe SK; Rajakaruna RHMG; Samarasinghe RANKK; Williams S; Mettananda S
BMJ Open; 2024 Feb; 14(2):e077342. PubMed ID: 38331857
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
Pepe A; Meloni A; Capra M; Cianciulli P; Prossomariti L; Malaventura C; Putti MC; Lippi A; Romeo MA; Bisconte MG; Filosa A; Caruso V; Quarta A; Pitrolo L; Missere M; Midiri M; Rossi G; Positano V; Lombardi M; Maggio A
Haematologica; 2011 Jan; 96(1):41-7. PubMed ID: 20884710
[TBL] [Abstract][Full Text] [Related]
7. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
[TBL] [Abstract][Full Text] [Related]
8. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.
Forni GL; Podestà M; Musso M; Piaggio G; Musallam KM; Balocco M; Pozzi S; Rosa A; Frassoni F
Haematologica; 2013 Apr; 98(4):555-9. PubMed ID: 23242593
[TBL] [Abstract][Full Text] [Related]
12. Effects on hearing after long-term use of iron chelators in beta-thalassemia: Over twenty years of longitudinal follow-up.
Aldè M; Ambrosetti U; Giuditta M; Cassinerio E; Piatti G
Auris Nasus Larynx; 2024 Apr; 51(2):271-275. PubMed ID: 37903661
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
Ricchi P; Meloni A; Pistoia L; Gamberini MR; Cuccia L; Allò M; Putti MC; Spasiano A; Rosso R; Cecinati V; Righi R; Renne S; Peritore G; Vallone A; Positano V; Quaia E; Cademartiri F; Pepe A
Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
[TBL] [Abstract][Full Text] [Related]
14. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
Saliba AN; El Rassi F; Taher AT
Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
[TBL] [Abstract][Full Text] [Related]
15. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
16. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.
Pennell DJ; Porter JB; Piga A; Lai YR; El-Beshlawy A; Elalfy M; Yesilipek A; Kilinç Y; Habr D; Musallam KM; Shen J; Aydinok Y;
Am J Hematol; 2015 Feb; 90(2):91-6. PubMed ID: 25345697
[TBL] [Abstract][Full Text] [Related]
17. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD
Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
[TBL] [Abstract][Full Text] [Related]
18. No difference in myocardial iron concentration and serum ferritin with deferasirox and deferiprone in pediatric patients with hemoglobinopathies: A systematic review and meta-analysis.
Saleem A; Waqar E; Shuja SH; Naeem U; Moeed A; Rais H; Ahmed J
Transfus Clin Biol; 2023 Feb; 30(1):69-74. PubMed ID: 35878782
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
[TBL] [Abstract][Full Text] [Related]
20. Comparative Efficacy and Safety of Oral Iron Chelators and their Novel Combination in Children with Thalassemia.
Gomber S; Jain P; Sharma S; Narang M
Indian Pediatr; 2016 Mar; 53(3):207-10. PubMed ID: 27029681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
